← All peptides
verifiedBioGate · GREENGrade B

PT-141 (Bremelanotide)

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Melanocortin-4 receptor agonist; FDA-approved (Vyleesi) for premenopausal HSDD via central melanocortin signaling.

cyclic lactamacetylated N-terminusNle¹
MW
1025.18
Length
42aa
Posterior
65.0%
Structural preview · ESMFold-2 mockdeterministic per sequence
Backbone preview · cyclic lactam
PDA-V1 attestation

Cryptographic chain of custody.

Outer PDA hash
Inputs hash
Merkle root
TEE attestation
Protocol version
PDA-V1
Source
peptide-md
Model version
structure-fm-2026.04
Candidates emitted
6
Signed
2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with @peptide-md/verifier.
Verify this attestation →Download dossier (PDF)Compare with…
Real-world evidence

Cohort-attested outcomes.

Cohorts
4
Participants
495
Mean Δ
+7.21
Δ HRV ms (8-week) · 95% CI [5.99, 8.44]
IPNFT - Not minted

This peptide is not currently represented as an IPNFT. Cohort outcomes feed back into the unminted pool.

Citations

Source literature.

Grade A2019 · Obstet Gynecol

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder

Kingsberg SA et al.

PMID 30923458